Represents the amount of seeking an award in this second arbitration.

No definition available.

Name:	gmab_AmountOfSeekingAwardInSecondArbitration
Namespace Prefix:	gmab_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The percentage of profits sharing for the product of Tivdak.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationAgreementProfitsSharingPercentage
Namespace Prefix:	gmab_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the cost and profit sharing ratio.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationsAgreementCostAndProfitSharingRatio
Namespace Prefix:	gmab_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash in flow from initial payments received.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationsAgreementInitialPaymentReceived
Namespace Prefix:	gmab_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of milestone payment receivable under an collaboration agreement.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationsAgreementMilestonePaymentReceivable
Namespace Prefix:	gmab_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The percentage of royalties of worldwide net sales ofatumumab for the treatment of non-cancer under the agreement.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationsAgreementNonCancerTreatmentRoyaltyPercentageOnWorldWideNetSales
Namespace Prefix:	gmab_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of lump sum payment received under an collaboration agreement for lost potential royalties.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationsAgreementPaymentReceivedForLostRoyalties
Namespace Prefix:	gmab_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the royalties expiration term after the first sale of each licensed product in such country.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationsAgreementRoyaltiesExpirationTermAfterFirstSaleOfEachLicensedProduct
Namespace Prefix:	gmab_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of royalties under collaboration agreement.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationsAgreementRoyaltiesPercentage
Namespace Prefix:	gmab_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Term from first sale of the product after which obligation to pay royalties under the agreement will expire.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationsAgreementRoyaltyObligationExpirationTermAfterFirstSaleOfProduct
Namespace Prefix:	gmab_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of tiered royalty under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationsAgreementTieredRoyaltyPercentage
Namespace Prefix:	gmab_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of upfront fee payment made under an collaboration agreement.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationsAgreementUpfrontFeePaid
Namespace Prefix:	gmab_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The identified transaction price under the contract.

+ References

No definition available.

+ Details

Name:	gmab_ContractTransactionPrice
Namespace Prefix:	gmab_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The percentage of discover research and development cost responsible by the entity.

+ References

No definition available.

+ Details

Name:	gmab_DiscoverResearchAndDevelopmentCostResponsibilityPercent
Namespace Prefix:	gmab_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the maximum number of product concepts for which a cost-plus margin approach was utilized for co-development activities.

+ References

No definition available.

+ Details

Name:	gmab_MaximumNumberOfProductConceptsForWhichCostPlusMarginApproachWasUtilized
Namespace Prefix:	gmab_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the new royalty term entitled from the date of DARZALEX FASPRO's first commercial sale as mentioned in declaration in second arbitration.

+ References

No definition available.

+ Details

Name:	gmab_NewRoyaltyObligationTermFromDateOfFirstCommercialSaleOfProduct
Namespace Prefix:	gmab_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The notice period after which company is solely responsible for the further development of DuoHexaBody-CD37.

+ References

No definition available.

+ Details

Name:	gmab_NoticePeriodForSolelyResponsibleForFurtherDevelopmentOfProduct
Namespace Prefix:	gmab_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of additional programs party to the agreement is entitled to work on.

+ References

No definition available.

+ Details

Name:	gmab_NumberOfAdditionalProgramEntitledToBeWorked
Namespace Prefix:	gmab_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of delivery license programs.

+ References

No definition available.

+ Details

Name:	gmab_NumberOfDeliveryLicenses
Namespace Prefix:	gmab_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the number of investigational medicines currently in clinical development.

+ References

No definition available.

+ Details

Name:	gmab_NumberOfInvestigationalMedicinesCurrentlyInClinicalDevelopment
Namespace Prefix:	gmab_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of license exercised under the agreement.

+ References

No definition available.

+ Details

Name:	gmab_NumberOfLicenseOptionsExercised
Namespace Prefix:	gmab_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of license options remaining to be exercised under the agreement.

+ References

No definition available.

+ Details

Name:	gmab_NumberOfOptionsRemainingToBeExercised
Namespace Prefix:	gmab_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of performance obligations.

+ References

No definition available.

+ Details

Name:	gmab_NumberOfPerformanceObligations
Namespace Prefix:	gmab_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of DuoBody-based products created under this collaboration were in active clinical development.

+ References

No definition available.

+ Details

Name:	gmab_NumberOfProductsWereInActiveClinicalDevelopment
Namespace Prefix:	gmab_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The ratio of share of profits before income taxes.

+ References

No definition available.

+ Details

Name:	gmab_RatioOfShareOfProfitsBeforeIncomeTaxes
Namespace Prefix:	gmab_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	instant

- Definition

The ratio of sharing pre tax profits during the period.

+ References

No definition available.

+ Details

Name:	gmab_RatioOfSharingPreTaxProfits
Namespace Prefix:	gmab_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the contractually entitled to receive an aggregate payment, related to additional development, regulatory and sales milestone payments for all programs.

+ References

No definition available.

+ Details

Name:	gmab_ReceivableAmountRelatedToAdditionalDevelopmentRegulatoryAndSalesMilestonePayments
Namespace Prefix:	gmab_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the contractually entitled to receive payments related to clinical development and commercial success.

+ References

No definition available.

+ Details

Name:	gmab_ReceivableAmountRelatedToClinicalDevelopmentAndCommercialSuccess
Namespace Prefix:	gmab_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

+ References

No definition available.

+ Details

Name:	gmab_ShareholdingsByBoardOfDirectorsAndExecutiveManagementLineItems
Namespace Prefix:	gmab_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash in flow from upfront milestone payments.

+ References

No definition available.

+ Details

Name:	gmab_UpfrontMilestonePaymentReceived
Namespace Prefix:	gmab_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 24
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 54
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_e&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2022-03-24
-Paragraph B16
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B16&doctype=Appendix&subtype=B
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_InvestmentAccountedForUsingEquityMethod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 54
-Subparagraph h
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_h&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 78
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_TradeAndOtherReceivables
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithJanssenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementWithJanssenDuobodyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithNovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithSeagenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithBointechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedOverTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	gmab_TypesOfRevenuesAxis=gmab_DevelopmentRegulatoryAndSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=gmab_ClinicalDevelopmentAndCommercialSuccessAcrossAllThreeProgramsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=gmab_SuccessOfAllFourNextGenerationAntibodyProductCandidatesDevelopedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Other Disclosures - Collaborations and Technology Licenses (Details) kr in Millions, $ in Millions				1 Months Ended				12 Months Ended
	Jun. 09, 2022 USD ($)	Jun. 10, 2020 DKK (kr) item product	Jun. 10, 2020 USD ($) item product	Sep. 30, 2021	Oct. 31, 2020	Jun. 30, 2020 DKK (kr)	Jun. 30, 2020 USD ($)	Dec. 31, 2022 USD ($) item Option	Dec. 31, 2021 USD ($)	Dec. 31, 2012	Dec. 31, 2022 DKK (kr) product	Dec. 31, 2022 USD ($) product	Dec. 31, 2021 DKK (kr)
Collaborations and Technology Licenses
Investments accounted for using equity method \| kr											kr 133		kr 371
Janssen
Collaborations and Technology Licenses
Royalty obligation expiration term after first sale of product								13 years
Amount of seeking an award	$ 405.0
New royalty term entitled as mentioned in declaration	13 years
Janssen (DuoBody)
Collaborations and Technology Licenses
Milestone payments receivable												$ 191.0
Upfront payment								$ 3.5
Number of additional programs \| item								10
Initial payments received								$ 2.0
Number of license exercised \| item								14
Number of license options remaining to be exercised \| Option								0
Number of products were in active clinical development \| product											3	3
Royalties expiration term after the first sale of each licensed product								10 years
Novartis (Arzaerra/Ofatumumab)
Collaborations and Technology Licenses
Royalty percentage for non-cancer treatment								10.00%
Lump sum payment received									$ 30.0
Seagen
Collaborations and Technology Licenses
Cost and profit sharing ratio					50
Profits sharing percentage				50.00%
AbbVie
Collaborations and Technology Licenses
Upfront payment						kr 4,911	$ 750.0
Ratio of share of profits before income taxes			50
Ratio of sharing pre tax profits		50	50
Number of performance obligations \| item		4	4
Number of delivery license programs \| item			3
Percentage of discover research and development cost responsible by the entity		100.00%	100.00%
Maximum number of product concepts for which cost-plus margin approach was utilized \| product		4	4
Contract Transaction Price		kr 4,911	$ 750.0
Notice period for solely responsible for further development of product				180 days
BioNTech
Collaborations and Technology Licenses
Upfront fee paid								$ 10.0
Number of investigational medicines currently in clinical development \| item								4
Performance obligations satisfied at point in time \| AbbVie
Collaborations and Technology Licenses
Contract Transaction Price		4,398	672.0
Performance obligations satisfied over time \| AbbVie
Collaborations and Technology Licenses
Contract Transaction Price		kr 513	$ 78.0
Bottom of range [member] \| Janssen
Collaborations and Technology Licenses
Tiered royalty percentage										12.00%
Bottom of range [member] \| Janssen (DuoBody)
Collaborations and Technology Licenses
Percentage of royalties								8.00%
Bottom of range [member] \| AbbVie
Collaborations and Technology Licenses
Tiered royalty percentage		22.00%	22.00%
Top of range [member] \| Janssen
Collaborations and Technology Licenses
Tiered royalty percentage										20.00%
Top of range [member] \| Janssen (DuoBody)
Collaborations and Technology Licenses
Milestone payments receivable												$ 175.0
Percentage of royalties								10.00%
Top of range [member] \| AbbVie
Collaborations and Technology Licenses
Tiered royalty percentage		26.00%	26.00%
Contractually entitled to receive amount in additional development, regulatory and sales milestone payments			$ 2,550.0
Contractually entitled to receive payments related to clinical development and commercial success			550.0
Development Regulatory and Sales Milestone \| Top of range [member] \| AbbVie
Collaborations and Technology Licenses
Receivables			3,150.0
Clinical Development and Commercial Success Across all Three Programs \| Development Regulatory and Sales Milestone \| AbbVie
Collaborations and Technology Licenses
Receivables			1,150.0
Success of all Four Next Generation Antibody Product Candidates Developed \| Development Regulatory and Sales Milestone \| AbbVie
Collaborations and Technology Licenses
Receivables			$ 2,000.0